Vani Madhuri Velavalapalli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vani Madhuri Velavalapalli has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Naresh Kumar Katari
School of Chemistry & Physics, College of Agriculture, Engineering & Science, Westville Campus University of KwaZulu‐Natal Durban South Africa
3 shared publications Rambabu Gundla
Department of Chemistry GITAM School of Science GITAM (Deemed to be University) Hyderabad Telangana India
3 shared publications- Baji Baba Shaik
Department of Pharmaceutical Chemistry College of Health Sciences University of KwaZulu‐Natal Durban South Africa
1 shared publication - Balakrishna Kolli
Department of Chemistry, School of Science, GITAM (Deemed to be University), Vishakhapatnam-530045, India
1 shared publication Dhilli Rao Gorja
Department of Chemistry, Texila American University, Georgetown, Guyana
1 shared publicationG Shiva Kumar
1 shared publication
Latest Publications
- Open Access
- 17 August 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (31)
Discovery of Spirochromanone‐Based Molecular Hybrids as Promising Anticancer Leads: An Integrated Experimental and Theoretical Study
Cancer remains one of the leading causes of mortality worldwide, emphasizing the urgent need for the discovery of novel and selective chemotherapeutic agents. In this study, a new series of spirochromanone‐based molecular hybrids was rationally designed and synthesized to explore their potential as anticancer agents. The synthesized compounds were fully characterized by spectroscopic techniques including NMR and LCMS. The in vitro cytotoxic evaluation of the synthesized hybrids against a panel of human cancer cell lines (A549, HCT116, U2OS, Jurkat, CCRF‐CEM, MOLT‐4, RAMOS, K562, MRC‐5, and BJ cell lines) were assessed. Among all the compounds, 6b , 6c , 6g , 6h , and 6j have been displayed promising inhibition against RAMOS cell lines with an IC 50 range of 1.11–1.47 µM, respectively. In addition, compounds 6c , 6j , 6b , and 6f have been found to have potential inhibition against CCRF‐CEM cell lines with an IC 50 range of 7.71–13.55 µM. Furthermore, molecular docking studies were performed to explore the possible binding modes of the designed compounds within the active sites of ITK and BTK as a preliminary computational assessment. In silico ADMET analysis further supported the drug‐like nature and acceptable pharmacokinetic profiles of the active hybrids.
- 17 August 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (31)
Open AccessDiscovery of Spirochromanone‐Based Molecular Hybrids as Promising Anticancer Leads: An Integrated Experimental and Theoretical Study
Cancer remains one of the leading causes of mortality worldwide, emphasizing the urgent need for the discovery of novel and selective chemotherapeutic agents. In this study, a new series of spirochromanone‐based molecular hybrids was rationally designed and synthesized to explore their potential as anticancer agents. The synthesized compounds were fully characterized by spectroscopic techniques including NMR and LCMS. The in vitro cytotoxic evaluation of the synthesized hybrids against a panel of human cancer cell lines (A549, HCT116, U2OS, Jurkat, CCRF‐CEM, MOLT‐4, RAMOS, K562, MRC‐5, and BJ cell lines) were assessed. Among all the compounds, 6b , 6c , 6g , 6h , and 6j have been displayed promising inhibition against RAMOS cell lines with an IC 50 range of 1.11–1.47 µM, respectively. In addition, compounds 6c , 6j , 6b , and 6f have been found to have potential inhibition against CCRF‐CEM cell lines with an IC 50 range of 7.71–13.55 µM. Furthermore, molecular docking studies were performed to explore the possible binding modes of the designed compounds within the active sites of ITK and BTK as a preliminary computational assessment. In silico ADMET analysis further supported the drug‐like nature and acceptable pharmacokinetic profiles of the active hybrids.
- Open Access
- 18 May 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (29) , 26273-26291
New phenylcyclopropane-carbohydrazide furan derivatives with potent anticancer activity and EGFR inhibitory potential
Fifteen new phenylcyclopropane-carbohydrazide-containing furan derivatives are synthesised and thoroughly characterized using FT-IR, 1 H-NMR, 13 C-NMR, and HRMS spectroscopy techniques in the search for new anticancer drugs.
- 18 May 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (29) , 26273-26291
Open AccessNew phenylcyclopropane-carbohydrazide furan derivatives with potent anticancer activity and EGFR inhibitory potential
Fifteen new phenylcyclopropane-carbohydrazide-containing furan derivatives are synthesised and thoroughly characterized using FT-IR, 1 H-NMR, 13 C-NMR, and HRMS spectroscopy techniques in the search for new anticancer drugs.
- 31 January 2024
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1304
Development and evaluation of new oxindole derivatives as potential anti-tubercular agents
- 31 January 2024
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1304
Development and evaluation of new oxindole derivatives as potential anti-tubercular agents